Headache and Migraine

NeurologyLive's editor in chief Stephen D. Silberstein, MD, discusses the importance of considering treatment contraindications in the context of individual patients.

Mia Minen, MD, MPH, sat down for an interview to discuss why behavioral therapies could be an effective and easily accessible treatment for posttraumatic headaches following events like concussions.

At the 2019 American Academy of Neurology Conference, Mia Minen, MD, MPH took the time to sit down and discuss the behavioral therapies associated with treating migraine.

Neurology News Network for the week ending October 19, 2019.

At the 2019 American Academy of Neurology Annual Meeting, Mia Minen, MD, MPH, discussed the opportunities that the increasing number of mobile health users presents for migraine treatment.

Alder Biopharmaceuticals announced the dosing of the first patient with ALD1910, its investigational monoclonal antibody that inhibits PACAP to prevent migraine. The study is aiming to enroll 100 individuals with results in mid-to-late 2020.

Neurology News Network for the week ending October 12, 2019.

Eli Lilly’s lasmiditan (Reyvow) tablets are the first member of the ditan class approved for use in adults with migraine with or without aura, offering patients who have an inadequate response to other therapies a new acute treatment option.

New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.

As vestibular migraine is a common cause of vertigo, the results, which need to be confirmed with larger studies, suggest some potential for an effective and easy to use treatment for patients.

Originally approved by the FDA in January, sumatriptan nasal spray was acquired by Upsher-Smith in a territory rights agreement with Dr. Reddy’s Laboratories in June, as well as its 3-mg injection formulation (Zembrace SymTouch).

Despite early reservations, available literature suggests that it may be time to invest in the utilization of wellness-based methods in the treatment of migraine.

New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.

After a long period of time with minimally effective treatments for migraine, the growing understanding of the CGRP pathway has opened the door to a variety of new and highly efficacious therapies for patients with chronic and episodic forms of disease.

Reproductive considerations and hormonal fluctuations throughout a woman’s life require careful consideration when treating migraine.

Reducing the frequency of migraine is only 1 step in the process of optimizing management and addressing the disease's impact on patients’ lives.

Neurology News Network for the week ending September 21, 2019.

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City.

Impel NeuroPharma's nasal dihydroergotamine mesylate acute migraine therapy INP104 has shown excellent pharmacokinetic data, and is set to be assessed in a 24-week trial with a planned 28-week extension.

The director of the Montefiore Headache Center will provide further insight into migraine care at the 1st Annual International Congress on the Future of Neurology, to be held September 27-28 in New York City.

The distinguished professor and director of cell biology at Missouri State University discussed the use of nVNS in migraine treatment and whether or not it can replace the use of or be used in conjunction with triptans—a medication on which many patients fail or report poor response on.

The distinguished professor and director of cell biology at Missouri State University discussed the findings of a model of nVNS which suggested it operates through a novel mechanism compared to available migraine therapies.

Neurology News Network for the week ending August 24, 2019.

Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.

NeurologyLive Editor in Chief Stephen D. Silberstein, MD discusses the importance of reaching a treatment effect that makes a significant difference in patients' lives.

Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.

The child neurology resident at NYU Langone spoke about ways for residents to identify and address impaired colleagues that suffer from depression and burnout.

Those with an existing inventory of eletriptan hydrobromide 40 mg tablets, lots AR5407 and CD4565, should stop use and distribution, and quarantine immediately.

The director of the MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the ongoing efforts in drug development and what the ideal future may hold for migraine medicine.

The associate chief of the MS division and professor of neurology at the University of Pennsylvania described the relationship between artificial intelligence and medicine, and how he sees it evolving in the future.